Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCarey, Lisa
dc.contributor.authorLoirat, Delphine
dc.contributor.authorPunie, Kevin
dc.contributor.authorBardia, Aditya
dc.contributor.authorDieras, Veronique
dc.contributor.authorDalenc, Florence
dc.contributor.authorCortés Castan, Javier
dc.date.accessioned2022-09-09T07:45:33Z
dc.date.available2022-09-09T07:45:33Z
dc.date.issued2022-06-09
dc.identifier.citationCarey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, et al. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 9;8:72.
dc.identifier.issn2374-4677
dc.identifier.urihttp://hdl.handle.net/11351/8091
dc.descriptionCàncer de mama; Tractament de segona línia
dc.description.sponsorshipThis study was sponsored by Gilead Sciences, Inc.
dc.language.isoeng
dc.publisherNature Research
dc.relation.ispartofseriesNPJ Breast Cancer;8
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Tractament
dc.subjectAnticossos monoclonals - Ús terapèutic
dc.subject.meshTriple Negative Breast Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshImmunoconjugates
dc.titleSacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41523-022-00439-5
dc.subject.decsneoplasias de mama triple negativos
dc.subject.decs/farmacoterapia
dc.subject.decsinmunoconjugados
dc.relation.publishversionhttps://doi.org/10.1038/s41523-022-00439-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Carey LA] University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. [Loirat D] Medical Oncology Department and D3i, Institut Curie, Paris, France. [Punie K] Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. [Bardia A] Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. [Diéras V] Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. [Dalenc F] Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France. [Cortés J] International Breast Cancer Center, Quirón Group, Barcelona, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid. Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35680967
dc.identifier.wos000809031400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple